Abstract
Parkinson’s disease is a common age-related progressive neurodegenerative disorder. Over the last 10 years, advances have been made in our understanding of the etiology of the disease with the greatest insights perhaps coming from genetic studies, including genome-wide association approaches. These large scale studies allow the identification of genomic regions harboring common variants associated to disease risk. Since the first genome-wide association study on sporadic Parkinson’s disease performed in 2005, improvements in study design, including the advent of meta-analyses, have allowed the identification of ~21 susceptibility loci. The first loci to be nominated were previously associated to familial PD (SNCA, MAPT, LRRK2) and these have been extensively replicated. For other more recently identified loci (SREBF1, SCARB2, RIT2) independent replication is still warranted. Cumulative risk estimates of associated variants suggest that more loci are still to be discovered. Additional association studies combined with deep re-sequencing of known genome-wide association study loci are necessary to identify the functional variants that drive disease risk. As each of these associated genes and variants are identified they will give insight into the biological pathways involved the etiology of Parkinson’s disease. This will ultimately lead to the identification of molecules that can be used as biomarkers for diagnosis and as targets for the development of better, personalized treatment.
Keywords: Sporadic Parkinson’s disease, Genetics, Genome-wide association studies.
Current Genomics
Title:Association Studies of Sporadic Parkinson’s Disease in the Genomic Era
Volume: 15 Issue: 1
Author(s): Catherine Labbe and Owen A. Ross
Affiliation:
Keywords: Sporadic Parkinson’s disease, Genetics, Genome-wide association studies.
Abstract: Parkinson’s disease is a common age-related progressive neurodegenerative disorder. Over the last 10 years, advances have been made in our understanding of the etiology of the disease with the greatest insights perhaps coming from genetic studies, including genome-wide association approaches. These large scale studies allow the identification of genomic regions harboring common variants associated to disease risk. Since the first genome-wide association study on sporadic Parkinson’s disease performed in 2005, improvements in study design, including the advent of meta-analyses, have allowed the identification of ~21 susceptibility loci. The first loci to be nominated were previously associated to familial PD (SNCA, MAPT, LRRK2) and these have been extensively replicated. For other more recently identified loci (SREBF1, SCARB2, RIT2) independent replication is still warranted. Cumulative risk estimates of associated variants suggest that more loci are still to be discovered. Additional association studies combined with deep re-sequencing of known genome-wide association study loci are necessary to identify the functional variants that drive disease risk. As each of these associated genes and variants are identified they will give insight into the biological pathways involved the etiology of Parkinson’s disease. This will ultimately lead to the identification of molecules that can be used as biomarkers for diagnosis and as targets for the development of better, personalized treatment.
Export Options
About this article
Cite this article as:
Labbe Catherine and Ross A. Owen, Association Studies of Sporadic Parkinson’s Disease in the Genomic Era, Current Genomics 2014; 15 (1) . https://dx.doi.org/10.2174/1389202914666131210212745
DOI https://dx.doi.org/10.2174/1389202914666131210212745 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Inflammation, Immunity, and Alzheimers Disease (Guest Editor: Terrence Town)]
CNS & Neurological Disorders - Drug Targets Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology The Effects of Gender and CYP46 and Apo E Polymorphism on 24S-Hydroxycholesterol Levels in Alzheimers Patients Treated with Statins
Current Alzheimer Research Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research Hippocampal Subfield Atrophies in Converted and Not-Converted Mild Cognitive Impairments Patients by a Markov Random Fields Algorithm
Current Alzheimer Research Multivariate Optimization Model in a Partial Least Squares-1 Method for Simultaneous Determination of Dorzolamide Hydrochloride and Timolol Maleate in Eye Drops
Current Pharmaceutical Analysis Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research Decreased Plasma Level of Lipoprotein Lipase Predicted Verbal Disfluency in Chinese Type 2 Diabetes Mellitus Patients with Early Cognitive Deficits
Current Alzheimer Research Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease
Current Medicinal Chemistry Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Influence of Hypertension, Alone and in Combination with Other Vascular Risk Factors on Cognition
CNS & Neurological Disorders - Drug Targets Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Pneumonia in the Elderly
Current Respiratory Medicine Reviews Genes and Hypertension
Current Pharmaceutical Design Responders to ChEI Treatment of Alzheimers Disease Show Restitution of Normal Regional Cortical Activation
Current Alzheimer Research Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design